The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) α-308 G/G promoter polymorphism-Reference-Cited by-同舟云学术

The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) α-308 G/G promoter polymorphism

Published:2011-01-14 Issue:3 Volume:30 Page:391-395
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Soto Lilian,Sabugo Francisca,Catalan Diego,Wurmann Pamela,Cermenatti Tomás,Gatica Héctor,Aravena Octavio,Salazar Lorena,Aguillón Juan Carlos,Cuchacovich Miguel

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s10067-011-1679-4.pdf

Reference19 articles.

1. van der Woude D, Huizinga TW (2008) Translating basic research into clinical rheumatology. Best Pract Res Clin Rheumatol 22:299–310

2. Senolt L, Vencovsky J, Pavelka K, Ospelt C, Gay S (2009) Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 9:102–107

3. Lee YH, Ji JD, Bae SC, Song GG (2010) Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update. Rheumatol 37:740–746

4. Marotte H, Miossec P (2010) Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis. Joint Bone Spine 77:297–305

5. Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D et al (2006) Tumor necrosis factor-α -308 G/G promoter polymorphism and TNF-α levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol 35:435–440

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis?;Reumatología Clínica;2024-08

2. Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis?;Reumatología Clínica (English Edition);2024-08

3. Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis;Rheumatology and Therapy;2022-11-27

4. The Clinical Impact of Seropositivity on Treatment Response in Patients with Rheumatoid Arthritis Treated with Etanercept: A Real-World Iraqi Experience;Open Access Rheumatology: Research and Reviews;2022-06

5. Toward Overcoming Treatment Failure in Rheumatoid Arthritis;Frontiers in Immunology;2021-12-23